TY - JOUR
T1 - Trends in Cardiac Tamponade Among Recipients of Permanent Pacemakers in the United States
T2 - From 2008 to 2012
AU - Moazzami, Kasra
AU - Dolmatova, Elena
AU - Kothari, Neil
AU - Mazza, Victor
AU - Klapholz, Marc
AU - Waller, Alfonso H.
N1 - Publisher Copyright:
© 2017 American College of Cardiology Foundation
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Objectives The aim of this study was to describe the trends and predictors of cardiac tamponade among permanent pacemaker (PPM) recipients in the United States between 2008 and 2012. Background Limited data exist regarding the burden, trend, and predictors of tamponade in patients following PPM implantation. Methods The National (Nationwide) Inpatient Sample database was used to identify PPM implantations between 2008 and 2012. Results Among 922,549 patients who received PPM devices between 2008 and 2012, cardiac tamponade occurred in 2,595 patients (0.28%). Overall, in-hospital cardiac tamponade rates increased by 35% among recipients of PPMs. The incidence rate steadily increased from 0.26% in 2008 to 0.35% in 2012 (p < 0.0001). Although the mean age (p = 0.28) and sex distribution (p = 0.25) did not change over the years, the rate of in-hospital mortality increased among patients who developed tamponade from 2008 to 2012 (p = 0.014). After multivariate adjustment for patient and hospital characteristics, female sex (odds ratio [OR]: 1.23; 95% confidence interval [CI]: 1.04 to 1.54; p = 0.011), dual-chamber pacemakers (OR: 1.68; 95% CI: 1.17 to 2.41; p < 0.004), and chronic liver disease (OR: 3.18; 95% CI: 1.92 to 5.64; p < 0.001) were found to be independently associated with a greater odds of cardiac tamponade. Conversely, hypertension (OR: 0.71; 95% CI: 0.45 to 0.94; p = 0.021) and atrial fibrillation (OR: 0.78; 95% CI; 0.61 to 0.96; p = 0.002) were associated with lower odds of tamponade. Conclusions The burden of cardiac tamponade associated with PPM implantation has steadily increased in the United States. Specific patient factors were identified that could predict the risk for developing tamponade among PPM recipients.
AB - Objectives The aim of this study was to describe the trends and predictors of cardiac tamponade among permanent pacemaker (PPM) recipients in the United States between 2008 and 2012. Background Limited data exist regarding the burden, trend, and predictors of tamponade in patients following PPM implantation. Methods The National (Nationwide) Inpatient Sample database was used to identify PPM implantations between 2008 and 2012. Results Among 922,549 patients who received PPM devices between 2008 and 2012, cardiac tamponade occurred in 2,595 patients (0.28%). Overall, in-hospital cardiac tamponade rates increased by 35% among recipients of PPMs. The incidence rate steadily increased from 0.26% in 2008 to 0.35% in 2012 (p < 0.0001). Although the mean age (p = 0.28) and sex distribution (p = 0.25) did not change over the years, the rate of in-hospital mortality increased among patients who developed tamponade from 2008 to 2012 (p = 0.014). After multivariate adjustment for patient and hospital characteristics, female sex (odds ratio [OR]: 1.23; 95% confidence interval [CI]: 1.04 to 1.54; p = 0.011), dual-chamber pacemakers (OR: 1.68; 95% CI: 1.17 to 2.41; p < 0.004), and chronic liver disease (OR: 3.18; 95% CI: 1.92 to 5.64; p < 0.001) were found to be independently associated with a greater odds of cardiac tamponade. Conversely, hypertension (OR: 0.71; 95% CI: 0.45 to 0.94; p = 0.021) and atrial fibrillation (OR: 0.78; 95% CI; 0.61 to 0.96; p = 0.002) were associated with lower odds of tamponade. Conclusions The burden of cardiac tamponade associated with PPM implantation has steadily increased in the United States. Specific patient factors were identified that could predict the risk for developing tamponade among PPM recipients.
KW - National Inpatient Sample
KW - mortality
KW - pacemakers
KW - tamponade
UR - http://www.scopus.com/inward/record.url?scp=84998799656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84998799656&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2016.05.009
DO - 10.1016/j.jacep.2016.05.009
M3 - Article
C2 - 29759693
AN - SCOPUS:84998799656
SN - 2405-500X
VL - 3
SP - 41
EP - 46
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 1
ER -